flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 reduced the risk of clinically important and death from cardiovascular (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 🔴Cardiovascular outcomes with semaglutide by
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16





.jpg)





















